​​​
  1. Suven Life Sciences begins clinical trial of antidepressant

Suven Life Sciences begins clinical trial of antidepressant

Drug firm Suven Life Sciences today announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of major depressive disorder.

By: | New Delhi | Published: May 25, 2017 11:44 AM
Suven Life Sciences shares were trading 1.01 per cent up at Rs 75.80 on BSE in morning trade. (Reuters)

Drug firm Suven Life Sciences today announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of major depressive disorder. In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a “novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing… and the topline results from the study is expected during the quarter Jan-March 2018”.

Suven Life CEO Venkat Jasti said: “Progression of SUVN- 911 into phase 1 clinical development is a significant achievement in enhancing our clinical pipeline beyond Dementia into mental illness arena, Major Depressive Disorder (MDD).”

Also watch:

Suven Life said the global antidepressant market is valued over $20 billion. Suven Life Sciences shares were trading 1.01 per cent up at Rs 75.80 on BSE in morning trade.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

  1. No Comments.

Go to Top